Cidara Therapeutics, Inc.
cidara.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 6, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Feb 17, 2026.
10-Q for Q3 FY2025, filed Nov 6, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops medicines combining a drug with an antibody fragment to prevent influenza and treat solid tumors.
10-K for FY2024, filed Mar 6, 2025We are a biotechnology company using our proprietary Cloudbreak® platform to develop drug-Fc conjugate, or DFC, immunotherapies designed to…View ↗
DFCs are fundamentally different from ADCs: DFCs are biologically stable drug-Fc conjugates designed to engage extracellular targets, while…View ↗
Our lead Cloudbreak candidate for the prevention of influenza is CD388, a highly potent antiviral designed to deliver universal prevention…View ↗
Using Cloudbreak, we seek to develop a new generation of immunotherapies targeting the tumor microenvironment. Our lead oncology DFC…View ↗
How Did They Make Money?
$1.3M
-
10-K for FY2024, filed Mar 7, 2025
$1.3M ↗
Did Revenues Turn Into Profits?
No. It lost $169.8M in FY2024.
10-K for FY2024, filed Mar 7, 2025
−$176.1MView ↗
10-K for FY2024, filed Mar 7, 2025
−$169.8MView ↗
10-K for FY2024, filed Mar 7, 2025
−$176.7MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2025, filed Nov 7, 2025
−$83.2MView ↗
- ▲ +421% (Loss)
- vs −$16M in Q3 FY2024
-
Jan 7, 2026
Cidara became a wholly owned subsidiary following a merger
Sources
8-K, filed Jan 7, 2026
Also on January 7, 2026, following consummation of the Offer, Purchaser merged with and into the Company, with the Company being the…View ↗
From antifungal to antiviral focus
The older report identifies rezafungin as its lead candidate and describes Cloudbreak programs; the latest says it sold rezafungin and focuses research and development on Cloudbreak, with its influenza program as its most advanced.
10-K for FY2021, filed Mar 7, 2022 10-K for FY2024, filed Mar 6, 2025We are a biotechnology company focused on the discovery, development and commercialization of long-acting therapeutics designed to…View ↗
Who Did They Compete With?
Competes with Arcus Biosciences and AstraZeneca
10-K for FY2024, filed Mar 6, 2025For certain patient populations and approved indications, we expect that CD388 will be used in conjunction with approved vaccines for…View ↗
Loading...
